Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Millipore Announces Exclusive Agreement with Julphar Diabetes

Published: Wednesday, August 08, 2012
Last Updated: Wednesday, August 08, 2012
Bookmark and Share
Collaboration to offer non-animal origin, recombinant human insulin as cell culture media supplement.

Merck Millipore announced an exclusive agreement to sell recombinant human insulin manufactured by the United Arab Emirates-based pharmaceutical production company Julphar Diabetes. The insulin is of non-animal origin and will be marketed under Merck Millipore's CellPrime™ brand name, complementing the company's range of non-animal origin supplements for cell culture biomanufacturing.
 
CellPrime™ Insulin stimulates the proliferation of cells and aids in carbohydrate metabolism, helping to ensure the long-term viability of various cell lines. It also effectively enhances cell growth rate and therapeutic protein production, while preventing morphological abnormalities of the cells.
 
"CellPrime™ Insulin will help the biopharmaceutical industry enhance cell culture performance without sacrificing safety," said Burghard Freiberg, Senior Vice President Pharm Chemicals Solutions. "Owing to its non-animal origin, its consistent manufacturing process and the traceability of its raw materials it enables manufacturers of monoclonal antibodies and recombinant biologics to use an insulin supplement that is both safe and effective."
 
Joe Saldanha, GM of Julphar Diabetes said, "This agreement marks a significant achievement for Julphar Diabetes and demonstrates the global impact that the state of the art manufacturing facility is set to make on the diabetes drug industry worldwide. We are proud to be associated with such a strong partner in the Life Science sector.''
 
Julphar Diabetes is the division of Julphar that manages the manufacturing and commercialization of diabetes products. The Julphar Diabetes facility (Julphar XI) is built in accordance with the latest EMEA regulations, utilizing the best available technologies in the market to comply with the latest international quality standards.
 
Merck Millipore partnered with Julphar Diabetes as its source for recombinant human insulin as the company has extensive experience in the production of pharmaceutical grade materials, currently manufacturing more than 800 drugs with distribution in 40 countries. The Julphar manufacturing process complies with current pharmacopeial standards and is animal-origin-free which helps ensure batch-to-batch consistency.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Enters Into Strategic Alliance with Turgut Ilaç
Company to provide Provantage® End-to-End solution for development and manufacture of biosimilars.
Friday, October 23, 2015
Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Expands Biomanufacturing Sciences and Training Center in Japan
Facility expansion and relocation of existing operations from Yokohama, Kanagawa Prefecture to Tokyo.
Thursday, August 28, 2014
Merck Millipore Invests €12M in France Facility
The investments will expand ready-to-use media manufacturing at company's Molshiem facility.
Tuesday, August 12, 2014
Merck Millipore Announces Incoming CEO and President
Udit Batra, Ph.D. will be responsible for the organization’s strategic direction to drive growth and product innovation as well as oversight of the worldwide operations.
Tuesday, April 15, 2014
Merck Millipore Announces Co-marketing Agreement with groninger
Offering combines industry-leading single-use assemblies, sterility assurance solutions and stainless steel filling equipment.
Tuesday, August 13, 2013
Merck KGaA Passes EXCiPACT Audit for Certification as Provider of Pharmaceutical Excipients
Ensures current GMP and GDP requirements applied to pharmaceutical excipients through a recognized auditing and certification process.
Friday, August 02, 2013
Merck Millipore Announces Opening of its GMP Bioproduction Facility in France
Enables accelerated process development and production of proteins/monoclonal antibodies.
Friday, September 21, 2012
Andrew Bulpin to Assume Leadership of Process Solutions at Merck Millipore
Bulpin appointed as head of the company's process solutions business unit.
Wednesday, May 02, 2012
Merck Millipore and CCRM Collaborate to Optimize Conditions for Large-scale Stem Cell Cultivation
Collaboration to deliver optimized methodologies for cultivation of stem cells on microcarriers in Mobius® CellReady bioreactor systems.
Tuesday, March 13, 2012
Scientific News
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!